COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer

Advance Prostate Cancer Consensus Conference 2021: Report

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma